Last $74.72 USD
Change Today +0.56 / 0.76%
Volume 1.6M
AZN On Other Exchanges
Symbol
Exchange
New York
Xetra
London
Stockholm
OTC US
Mexico
Berlin
As of 8:04 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

2 Kingdom Street

London, W2 6BD

United Kingdom

Phone: 44 20 7604 8000

Fax: 44 20 7604 8151

area of diabetic nephropathy. In September 2014, AstraZeneca plc and Eli Lilly and Co. announced that they reached a deal to jointly develop and commercialise AZD3293, an oral beta secretase cleaving enzyme or BACE inhibitor currently in development as a potential treatment for Alzheimer's disease. History The company was founded 1992. It was incorporated in England and Wales in 1992 under the Companies Act 1985. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in 1999.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZN:US $74.72 USD +0.56

AZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $59.06 USD -0.39
Bayer AG €112.33 EUR +0.32
Celgene Corp $93.85 USD +0.58
GlaxoSmithKline PLC 1,449 GBp +12.50
Novo Nordisk A/S kr281.70 DKK +0.10
View Industry Companies
 

Industry Analysis

AZN

Industry Average

Valuation AZN Industry Range
Price/Earnings 46.5x
Price/Sales 3.6x
Price/Book 4.3x
Price/Cash Flow 46.6x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC-SPONS ADR, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.